Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABPNASDAQ:CINGOTCMKTS:LTUSOTCMKTS:OASMY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.21-9.7%$0.23$0.15▼$13.00$14.35M-0.035.88 million shs3.89 million shsCINGCingulate$4.08+1.0%$4.12$1.80▼$20.83$17.15M-0.851.10 million shs84,094 shsLTUSLotus Pharmaceuticals$0.01+9.7%$0.01$0.00▼$0.01$20.89M-2.4845,038 shs14,558 shsOASMYOasmia Pharmaceutical$0.02$0.02$0.01▼$0.05N/A27.8645 shsN/A20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro+13.08%+5.83%+11.32%-45.37%+23,599,900.00%CINGCingulate-2.42%-10.42%+10.38%+1.00%+597.03%LTUSLotus Pharmaceuticals+9.72%+36.21%+36.21%+64.58%+139.39%OASMYOasmia Pharmaceutical0.00%0.00%0.00%0.00%-59.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/ACINGCingulate2.031 of 5 stars3.52.00.00.01.11.70.6LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOASMYOasmia PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,777.93% UpsideCINGCingulate 3.00Buy$26.00537.25% UpsideLTUSLotus Pharmaceuticals 0.00N/AN/AN/AOASMYOasmia Pharmaceutical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OASMY, CING, ABP, and LTUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$180K71.93N/AN/A($0.29) per share-0.73CINGCingulateN/AN/AN/AN/A$2.32 per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AOASMYOasmia Pharmaceutical$100KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-198.95%N/ACINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)LTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/AOASMYOasmia Pharmaceutical-$35.35MN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)Latest OASMY, CING, ABP, and LTUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AOASMYOasmia PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.110.11CINGCingulate0.161.871.87LTUSLotus PharmaceuticalsN/AN/AN/AOASMYOasmia PharmaceuticalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%CINGCingulate41.31%LTUSLotus PharmaceuticalsN/AOASMYOasmia PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipABPAbpro20.80%CINGCingulate17.06%LTUSLotus PharmaceuticalsN/AOASMYOasmia PharmaceuticalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million48.14 millionN/ACINGCingulate204.25 million3.52 millionNot OptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableOASMYOasmia Pharmaceutical20N/AN/ANot OptionableOASMY, CING, ABP, and LTUS HeadlinesRecent News About These CompaniesVivesto AB Reports Strategic Progress in Q1 2025May 10, 2025 | tipranks.comVivesto AB DRC (OASMY)October 19, 2024 | investing.comAstellas takes $170m charge as it drops DMD gene therapiesSeptember 5, 2024 | pharmaphorum.comVivesto AB ADR OASMYJanuary 20, 2024 | morningstar.comVivesto AB (VIVE) NPVOctober 13, 2023 | hl.co.ukVivesto AB (OASMY) Stock Historical Prices & Data - Yahoo FinanceAugust 29, 2023 | finance.yahoo.comOMX Stockholm Pharmaceuticals and Biotechnology GI (SX201030GI)July 19, 2023 | investing.comOMX Stockholm Health Care GI (SX20GI)June 4, 2023 | investing.comGlobal Pet Cancer Therapeutics Market Report to 2027 - Featuring Zoetis, AB Science, Karyopharm Therapeutics, Vivesto and Merial Among OthersFebruary 26, 2023 | benzinga.comOasmia Pharmaceutical AB ADR (OASMY)January 11, 2022 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeArcher's Midnight Air Taxi Soars, But Stock Doesn’t BudgeBy Jeffrey Neal Johnson | June 4, 2025View Archer's Midnight Air Taxi Soars, But Stock Doesn’t BudgeHims & Hers Stock: Buy the Dip or Wait It Out?By Gabriel Osorio-Mazilli | June 5, 2025View Hims & Hers Stock: Buy the Dip or Wait It Out?Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?By Jeffrey Neal Johnson | June 8, 2025View Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?Is Lululemon’s 18% Selloff Overdone? Analysts Say YesBy Gabriel Osorio-Mazilli | June 9, 2025View Is Lululemon’s 18% Selloff Overdone? Analysts Say YesOASMY, CING, ABP, and LTUS Company DescriptionsAbpro NASDAQ:ABP$0.21 -0.02 (-9.75%) As of 03:59 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Cingulate NASDAQ:CING$4.08 +0.04 (+0.99%) Closing price 04:00 PM EasternExtended Trading$4.22 +0.14 (+3.31%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0079 +0.00 (+9.72%) As of 06/23/2025 10:46 AM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.Oasmia Pharmaceutical OTCMKTS:OASMY$0.02 0.00 (0.00%) As of 06/20/2025Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
